TY - JOUR
T1 - Natural history of human papillomavirus and vaccinations in men
T2 - A literature review
AU - Lieblong, Benjamin J.
AU - Montgomery, Brooke E.E.
AU - Su, L. Joseph
AU - Nakagawa, Mayumi
N1 - Funding Information:
This work was supported in part by National Institutes of Health (National Cancer Institute) Grant R01 CA143130. The supporting funding source had no involvement in study design; collection, analysis, and interpretation of data; writing of this report; or the decision to submit this report for publication.
Publisher Copyright:
© 2019 The Authors. Health Science Reports published by Wiley Periodicals, Inc.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Background and aims: Infection with high-risk (HR) genotypes of the human papillomavirus (HPV) is necessary for and causative of almost all cervical cancers and their precursor condition, cervical intraepithelial neoplasia. These conditions have been sharply reduced by cervical cytology screening, and a further decrease is expected because of the recent introduction of prophylactic HPV vaccinations. While significant attention has been given to gynecologic HPV disease, men can be affected by HPV-related cancers of the anus, penis, and oropharynx. This literature review aims to address disparities in HPV-related disease in men, and certain HR male subpopulations, compared with women. Discussion: Overall, immunocompetent men are far less likely than women to develop anogenital HPV-related cancers, despite harboring HR HPV infections at anogenital sites. On the other hand, men who have sex with men and men living with human immunodeficiency virus infection are at considerably higher risk of HPV-related disease. Historic rates of prophylactic HPV vaccination in males have trailed those of females due to numerous multilevel factors, although, in recent years, this sex gap in vaccination coverage has been closing. In the absence of routine HPV screening in males, therapeutic vaccinations have emerged as a potential treatment modality for preinvasive neoplasia and are in various phases of clinical testing. Conclusion: Successful reductions in HPV disease morbidity at the population level must acknowledge and target HPV infections in men.
AB - Background and aims: Infection with high-risk (HR) genotypes of the human papillomavirus (HPV) is necessary for and causative of almost all cervical cancers and their precursor condition, cervical intraepithelial neoplasia. These conditions have been sharply reduced by cervical cytology screening, and a further decrease is expected because of the recent introduction of prophylactic HPV vaccinations. While significant attention has been given to gynecologic HPV disease, men can be affected by HPV-related cancers of the anus, penis, and oropharynx. This literature review aims to address disparities in HPV-related disease in men, and certain HR male subpopulations, compared with women. Discussion: Overall, immunocompetent men are far less likely than women to develop anogenital HPV-related cancers, despite harboring HR HPV infections at anogenital sites. On the other hand, men who have sex with men and men living with human immunodeficiency virus infection are at considerably higher risk of HPV-related disease. Historic rates of prophylactic HPV vaccination in males have trailed those of females due to numerous multilevel factors, although, in recent years, this sex gap in vaccination coverage has been closing. In the absence of routine HPV screening in males, therapeutic vaccinations have emerged as a potential treatment modality for preinvasive neoplasia and are in various phases of clinical testing. Conclusion: Successful reductions in HPV disease morbidity at the population level must acknowledge and target HPV infections in men.
KW - human papillomavirus
KW - men
KW - prophylactic vaccination
KW - therapeutic vaccination
UR - http://www.scopus.com/inward/record.url?scp=85076089112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076089112&partnerID=8YFLogxK
U2 - 10.1002/hsr2.118
DO - 10.1002/hsr2.118
M3 - Review article
C2 - 31139757
AN - SCOPUS:85076089112
SN - 2398-8835
VL - 2
JO - Health Science Reports
JF - Health Science Reports
IS - 5
M1 - e118
ER -